Skip to main content

Table 2 Changes of body mass index, skeletal muscle area, and adipose tissue area during the first-line FOLFIRINOX chemotherapy

From: Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients

Variables Subgroups Before chemotherapy After chemotherapy p-value Difference (after-before) Ratio (after/before)
BMI (kg/m2) Resection (n = 15) 22.7 ± 2.6 22.7 ± 2.8 0.935 0.0 ± 2.2 1.013 ± 0.104
No resection (n = 43) 21.3 ± 3.0 20.6 ± 3.2 0.013 − 0.7 ± 1.7 0.988 ± 0.078
Total (n = 58) 21.7 ± 2.9 21.2 ± 3.2 0.052 − 0.5 ± 1.8 0.997 ± 0.086
SM area (cm2) Resection (n = 15) 107.4 ± 26.6 107.8 ± 27.3 0.889 0.3 ± 9.2 1.006 ± 0.099
No resection (n = 43) 113.3 ± 24.4 96.2 ± 22.9  < 0.001 − 17.1 ± 13.6 0.853 ± 0.116
Total (n = 58) 111.8 ± 24.9 99.2 ± 24.4  < 0.001 − 12.6 ± 14.7 0.911 ± 0.130
AT area (cm2) Resection (n = 15) 211.4 ± 66.3 214.6 ± 63.4 0.832 3.2 ± 57.0 1.062 ± 0.353
No resection (n = 43) 198.8 ± 91.9 165.2 ± 83.4  < 0.001 − 33.6 ± 56.8 0.861 ± 0.253
Total (n = 58) 202.1 ± 85.6 178.0 ± 81.2 0.003 − 24.1 ± 58.7 0.889 ± 0.292
  1. The data are presented as mean ± standard deviation
  2. BMI body mass index, SM skeletal muscle, AT adipose tissue